[
1. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017;389:197-210.10.1016/S0140-6736(16)30677-8
]Search in Google Scholar
[
2. Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. Trends in Mortality from Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation. 2016;133:1916-1926.10.1161/CIRCULATIONAHA.115.018931
]Search in Google Scholar
[
3. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.10.1038/35025203
]Search in Google Scholar
[
4. Ross R. Atherosclerosis – An Inflammatory Disease. N Engl J Med. 1999;340:115-126.10.1056/NEJM199901143400207
]Search in Google Scholar
[
5. Libby P, Theroux P. Pathophysiology of Coronary Artery Disease. Circulation. 2005;111:3481-3488.10.1161/CIRCULATIONAHA.105.537878
]Search in Google Scholar
[
6. Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation. 2002;105:1135-1143.10.1161/hc0902.104353
]Search in Google Scholar
[
7. Conti P, Shaik-Dasthagirisaeb Y. Atherosclerosis: a chronic inflammatory disease mediated by mast cells. Cent Eur J Immunol. 2015;3:380-386.10.5114/ceji.2015.54603
]Search in Google Scholar
[
8. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med. 2005;352:1685-1695.10.1056/NEJMra043430
]Search in Google Scholar
[
9. Kuller L, Borthani N, Furberg C, et al. Prevalence of Subclinical Atherosclerosis and Cardiovascular Disease and Association with Risk Factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164-1179.10.1093/oxfordjournals.aje.a116963
]Search in Google Scholar
[
10. Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017;13:368-380.10.1038/nrneph.2017.51
]Search in Google Scholar
[
11. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic Susceptibility to Death from Coronary Heart Disease in a Study of Twins. N Engl J Med. 1994;330:1041-1046.10.1056/NEJM199404143301503
]Search in Google Scholar
[
12. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med. 2002;252:247-254.10.1046/j.1365-2796.2002.01029.x
]Search in Google Scholar
[
13. Musunuru K, Kathiresan S. Genetics of Coronary Artery Disease. Annu Rev Genomics Hum Genet. 2010;11:91-108.10.1146/annurev-genom-082509-141637
]Search in Google Scholar
[
14. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-861.10.1038/nature06258
]Search in Google Scholar
[
15. Green ED, Watson JD, Collins FS. Human Genome Project: Twenty-five years of big biology. Nature. 2015;526:29-31.10.1038/526029a
]Search in Google Scholar
[
16. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502:480-488.10.1038/nature12751
]Search in Google Scholar
[
17. Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014;74:98-102.10.1016/j.yjmcc.2014.05.002
]Search in Google Scholar
[
18. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. The Lancet. 2010;375:1525-1535.10.1016/S0140-6736(10)60452-7
]Search in Google Scholar
[
19. Zeller T, Blankenberg S. Blood-Based Gene Expression Tests: Promises and Limitations. Circ Cardiovasc Genet. 2013;6:139-140.10.1161/CIRCGENETICS.113.000149
]Search in Google Scholar
[
20. Perrino C, Barabási AL, Condorelli G, et al. Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2017;113:725-736.10.1093/cvr/cvx070
]Search in Google Scholar
[
21. Pedrotty DM, Morley MP, Cappola TP. Transcriptomic Biomarkers of Cardiovascular Disease. Prog Cardiovasc Dis. 2012;55:64-69.10.1016/j.pcad.2012.06.003
]Search in Google Scholar
[
22. Wang L. Mutation of MEF2A in an Inherited Disorder with Features of Coronary Artery Disease. Science. 2003;302:1578-1581.10.1126/science.1088477
]Search in Google Scholar
[
23. Weng L, Kavaslar N, Ustaszewska A, et al. Lack of MEF2A mutations in coronary artery disease. J Clin Invest. 2005;115:1016-1020.10.1172/JCI24186
]Search in Google Scholar
[
24. Xu DL, Tian HL, Cai WL, et al. Novel 6-bp deletion in MEF2A linked to premature coronary artery disease in a large Chinese family. Mol Med Rep. 2016;14:649-654.10.3892/mmr.2016.5297
]Search in Google Scholar
[
25. Rosenberg S. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Ann Intern Med. 2010;153:425.10.7326/0003-4819-153-7-201010050-00005
]Search in Google Scholar
[
26. Small EM, Frost RJA, Olson EN. MicroRNAs Add a New Dimension to Cardiovascular Disease. Circulation. 2010;121:1022-1032.10.1161/CIRCULATIONAHA.109.889048
]Search in Google Scholar
[
27. Varga ZV, Zvara Á, Faragó N, et al. MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic preand postconditioning: protectomiRs. Am J Physiol-Heart Circ Physiol. 2014;307:H216-H227.10.1152/ajpheart.00812.2013
]Search in Google Scholar
[
28. Eulalio A, Mano M, Ferro MD, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492:376-381.10.1038/nature11739
]Search in Google Scholar
[
29. De Windt LJ, Thum T. State-of-the-art on non-coding RNA bioinformatics, diagnostics and therapeutics in cardiovascular diseases. J Mol Cell Cardiol. 2015;89:1-2.10.1016/j.yjmcc.2015.11.021
]Search in Google Scholar
[
30. Greco CM, Condorelli G. Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nat Rev Cardiol. 2015;12:488-497.10.1038/nrcardio.2015.71
]Search in Google Scholar
[
31. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66:1142-1174.10.1124/pr.113.008300
]Search in Google Scholar
[
32. Gidlöf O, Johnstone AL, Bader K, et al. Ischemic Preconditioning Confers Epigenetic Repression of Mtor and Induction of Autophagy Through G9a-Dependent H3K9 Dimethylation. J Am Heart Assoc. 2016;5.10.1161/JAHA.116.004076
]Search in Google Scholar
[
33. Fernandes M, Patel A, Husi H. C/VDdb: A multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD). PLoS One. 2018;13:e0207371.10.1371/journal.pone.0207371
]Search in Google Scholar
[
34. Csont T, Murlasits Z, Ménesi D, et al. Tissue-specific Gene Expression in Rat Hearts and Aortas in a Model of Vascular Nitrate Tolerance. J Cardiovasc Pharmacol. 2015;65:485-493.10.1097/FJC.0000000000000218
]Search in Google Scholar
[
35. Kato N, Liang Y-Q, Ochiai Y, Jesmin S. Systemic evaluation of gene expression changes in major target organs induced by atorvastatin. Eur J Pharmacol. 2008;584:376-389.10.1016/j.ejphar.2008.01.043
]Search in Google Scholar
